Navigation Links
New Way to Track Stem Cell Migration Could Advance Treatments for Brain Tumors and More
Date:9/6/2013

Durham, NC (PRWEB) September 06, 2013

A new study in the current issue of STEM CELLS Translational Medicine shows how a team of scientists led by Rex Moats, Ph.D., and Karen Aboody, M.D., discovered a safe, effective way to track the migration and distribution of neural stem cells used in treating invasive brain tumors. Their method, which involves “pre-loading” the cells before transplantation with ultra-small, super paramagnetic iron oxide nanoparticles that can then be detected via magnetic resonance imaging (MRI), has been approved for clinical trials in humans and has the potential to greatly accelerate the search for new treatments for deadly brain tumors and other diseases.

Numerous stem cell-based therapies are currently under investigation, including an FDA-approved clinical trial focused on employing neural stem cells (NSCs) in delivering drugs targeting invasive brain tumors. “The ability to monitor the time course, migration and distribution of stem cells following transplantation into these patients would provide critical information for optimizing treatment regimens,” Dr. Moats said. “However, no effective cell-tracking methodology had yet garnered clinical acceptance.”

A labeling and imaging protocol using clinical grade ferumoxytol — an iron replacement product currently approved to treat iron deficiency anemia in patients with chronic kidney disease — has shown promise in some studies as a possible tracking agent. The Moats-Aboody team, in conjunction with Dr. Joseph A. Frank, a co-investigator at NIH, had previously demonstrated that the combination of ferumoxides with protamine sulfate showed promise in labeling the NSCs for this purpose.

In this most recent study, they wanted to build upon their work by testing how adding heparin to the ferumoxytol and protamine sulfate mix (a combination called HPF) might affect the NSC labeling.

The results showed great promise in the lab. “Additionally,” Dr. Aboody said, “when we tested it on mice with brain tumors we were able to track the NSC distribution using an MRI at multiple time-points following intracerebral or intravenous injection. The mice demonstrated no significant clinical or behavioral changes, no neuronal or systemic toxicities and no abnormal accumulation of iron in the liver or spleen.”

“Overall, we propose that ferumoxytol-labeling is an effective cell-tracking method that is safe for clinical use, contributing little to the risk side of a given risk/benefit analysis,” Dr. Moats concluded.

Dr. Moats is a member of the Department of Radiology at Children's Hospital of Los Angeles and University of Southern Californian’s Keck School of Medicine while Dr. Aboody is with the Department of Neurosciences at City of Hope National Medical Center & Beckman Research Institute in Duarte, Calif. The investigative team also included researchers from the National Institutes of Health, the University of Chicago and the University of British Columbia.

”An important aspect of advancing neural stem cells as a treatment for brain tumors is being able to track the cells’ ability to adequately target and distribute throughout the tumor sites,” said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. “The current study is important because it identifies an effective cell-tracking method that appears safe for clinical use.”

The full article, “MRI Tracking of Ferumoxytol-labeled Human Neural Stem Cells: Studies Leading to Clinical Use,” can be accessed at http://www.stemcellstm.com.

About STEM CELLS Translational Medicine: STEM CELLS TRANSLATIONAL MEDICINE (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS® (http://www.StemCells.com), in its 31th year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (http://www.TheOncologist.com), also a monthly peer-reviewed publication, in its 18th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11095784.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Better Ways Needed to Track Drug Safety: Report
2. Tracking Love, Lust in the Brain
3. Tracking the wave of success for Team GBs swimmers
4. AFTS Labs Partners With Physicians To Complement NY's Mandated I-STOP Tracking System For Pain Pill Prescriptions: A Recipe For A Safer Community
5. New study finds increase in track-related injuries among youth in the United States
6. Researchers offer new approach to track former prisoners access to community HIV care
7. Kids Track Injuries Surge in US
8. Cell-Based Tracking Devices Might Help Monitor Treatments
9. Mayo Clinic creates tool to track real-time chemical changes in brain
10. ONR system selected to help DoD track human subjects studies
11. Health Officials Tracking Salmonella Outbreak Linked to Pet Turtles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: